Digestive system neoplasm

Researchers are testing a new CAR-T cell therapy called KD-496 in people with advanced solid tumors, including gastric and pancreatic cancer, that have not responded to at least two prior treatments. The therapy uses a patient's own T cells, which are genetically modified to reco…

This trial tests a new way to treat rectal cancer without surgery. People with localized rectal cancer who cannot have or refuse surgery will receive external beam radiation followed by a high-dose internal radiation boost, using a 3D-printed guide and tungsten shielding to prote…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

The PURITY trial compares giving a three-drug chemotherapy combination before surgery with going straight to surgery in people with biliary tract cancer that can be removed but has a high risk of returning. Participants are adults under 75 with confirmed, non-metastatic biliary t…

This early-stage trial tests a personalized peptide vaccine for people with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC) or other tumors that share a specific genetic change (DNAJB1-PRKACA fusion). The vaccine is designed to train the body's immune cell…

This phase II trial tests whether a personalized DNA vaccine, tailored to each patient's tumor, can keep high-risk liver cancer from coming back after surgical removal. Participants who have no remaining signs of cancer after surgery will receive the vaccine plus an immune booste…

This rollover study allows up to 40 people with KRAS G12C-mutated lung or other solid tumors who are already benefiting from opnurasib in a Novartis trial to keep receiving the drug. Participants continue their current dose of opnurasib alone or with TNO155 or trametinib. The goa…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This study looks at people with early-stage gastrointestinal cancers that have a mismatch repair deficiency, a feature that can make tumors respond well to immunotherapy. Part A is a registry that tracks all such patients, whether they have surgery or immunotherapy. Part B follow…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This phase 2 trial tests whether two immunotherapy drugs, botensilimab and balstilimab, can clear tiny amounts of cancer DNA from the blood of people with stage II or III colorectal cancer who have completed standard treatment. The study enrolls 20 adults whose blood still shows …

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This phase 2 study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has spread and worsened after one prior treatment. The drug targets a specific protein on cancer cells. Researchers will measure how well it shrinks tumors and track side …

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This Phase 3 study tests a new drug, telisotuzumab adizutecan, combined with bevacizumab, against the standard treatment (LONSURF plus bevacizumab) in 700 adults with advanced colorectal cancer that has stopped responding to prior therapies. The goal is to see if the new combo sh…

This Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-phase trial is testing whether adding an experimental drug called ZEN003694 to two approved cancer drugs (cetuximab and encorafenib) can help patients with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study involves 30 a…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…

This phase 2 trial is testing whether giving the immunotherapy drug tislelizumab every 2 weeks or every 4 weeks, alongside standard chemotherapy, is safe and effective for Japanese patients with advanced esophageal cancer that cannot be removed by surgery. The study aims to find …

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…

This early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…

This phase 2 trial is testing whether adding an immunotherapy drug (adebrelimab) to a chemotherapy combo (NALIRIFOX) and radiation can improve outcomes for people with a certain type of locally advanced rectal cancer (pMMR/MSS). About 84 participants will be randomly assigned to …

Researchers are testing whether combining microwave ablation with infusions of a patient's own expanded immune cells helps people with small liver tumors. The trial enrolls adults with up to three tumors, each no larger than 5 cm, who are not eligible for surgery. After ablation,…

Researchers are testing whether adding two immunotherapy drugs, durvalumab and tremelimumab, to focused radiation before surgery changes the immune cell makeup inside liver tumors. The trial enrolls 30 people with a single liver tumor that can be removed surgically. Everyone rece…

This expanded access program provides velzatinib (GSK6042981) to patients with gastrointestinal stromal tumors (GIST) that have a KIT mutation and have already tried at least three prior treatments. The program is for people who have no satisfactory alternative, including approve…

This study tests a drug called tislelizumab for people in Nigeria with a specific type of colorectal cancer (mismatch repair deficient). The drug helps the immune system attack cancer cells. The study will check if the drug shrinks tumors and is safe. It includes 40 adults who ha…

This phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…

This phase 2 trial tests whether giving a powerful chemotherapy regimen called NALIRIFOX along with targeted radiation and the drug capecitabine can shrink pancreatic tumors enough to allow successful surgery. The study enrolls 60 people with borderline resectable or locally adva…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study is testing a drug called patritumab deruxtecan in children whose liver or muscle cancers have returned or not responded to treatment. The drug works like a smart bomb, attaching to a protein on cancer cells to deliver a toxic payload. The trial will check if it is safe…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This study tests a drug called I-DXd in 60 people with advanced esophageal cancer that has worsened after prior treatments. I-DXd is designed to attach to cancer cells and deliver a toxic payload to destroy them. The main goal is to see how many patients' tumors shrink or disappe…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This phase III trial tests whether adding the immunotherapy drug serplulimab to standard induction chemotherapy can allow patients with advanced nasopharyngeal cancer to skip concurrent chemotherapy during radiation. The study plans to enroll 456 adults aged 18-65 with stage II-I…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

This study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation wil…

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

This study tests new drug combinations (including an antibody-drug conjugate) with the immunotherapy pembrolizumab, with or without chemotherapy, for people with advanced esophageal cancer that cannot be removed by surgery or has spread. About 298 participants will join to see if…

This trial tests whether adding two drugs (surufatinib and camrelizumab) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 502 adults who have not had prior treatment for their advanced cancer will be randomly assigned to the new combo or …

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

This study tests whether a second round of targeted radiation therapy (177Lu-DOTATATE) works better than standard drugs (everolimus, sunitinib, or cabozantinib) for people with advanced neuroendocrine tumors of the digestive system that have spread and cannot be removed by surger…

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

This study tests whether adding a virus-based drug (pelareorep) to standard chemotherapy can help people with a specific type of advanced colorectal cancer that has stopped responding to initial treatment. About 60 adults whose cancer has spread and has certain genetic features (…

This study tests whether adding celecoxib to TAS-102 can clear tiny amounts of cancer DNA (ctDNA) in the blood of colorectal cancer patients who have finished standard chemotherapy. About 25 adults with stage II-IV colorectal cancer and no visible tumors on scans will take TAS-10…

This phase II trial tests whether adding the immunotherapy drug relatlimab to standard nivolumab maintenance therapy can extend the time before cancer grows or spreads in patients with recurrent or metastatic nasopharyngeal cancer linked to Epstein-Barr virus. Participants first …

This clinical trial is investigating whether an experimental drug called SHR-9839, when used alone or combined with standard chemotherapy and an immunotherapy drug, can help people with advanced esophageal squamous cell carcinoma. The study will include about 84 adults aged 18 to…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This study compares two schedules of the radioactive drug Lu177-Dotatate in 166 people with slow-growing midgut neuroendocrine tumors. One group gets the drug every 8 weeks (standard), the other every 16 weeks. The goal is to see if the less frequent schedule causes fewer blood-r…

This early-phase trial is testing an experimental drug called BMS-986504 alongside standard cancer treatments in 60 people with advanced cancers that have lost a gene called MTAP. The cancers include mesothelioma, stomach/esophageal cancer, and bladder cancer. The main goal is to…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study tests an experimental oral drug, GSK5460025, alone or with other cancer drugs, in adults whose solid tumors have specific genetic changes (dMMR or MSI-H). The goal is to see if the drug can shrink tumors and to check its safety. About 47 people with advanced cancers th…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study looks at whether adding radiation to the liver can improve outcomes for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that has spread. About 60 adults with at least one liver tumor 3 cm or larger will receive either standard therapy a…

This study tests an experimental pill called VS-7375, designed to block a specific cancer-driving protein (KRAS G12D). The trial includes people with metastatic colorectal cancer that has this mutation. Some participants receive VS-7375 alone, others get it combined with an antib…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…

This phase 2 trial is testing whether adding two extra drugs—bevacizumab and sintilimab—to the usual combination of irinotecan and cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to irinotecan. The study enrolls 160 adults with RAS wi…

Researchers are testing a new drug, VVD-133214, combined with pembrolizumab in people with advanced colorectal cancer that has MSI and/or dMMR. These tumors rely on a protein called Werner helicase to survive, and VVD-133214 is designed to block it. The trial compares the combina…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This early-stage trial tests a technique called PIPAC, which turns a chemotherapy drug (mitomycin C) into a mist and sprays it directly onto cancer spread inside the abdomen. It is for people with advanced gastrointestinal cancers that cannot be removed by surgery. The main goal …

Researchers are testing an experimental injectable drug called XNW28012 in people with metastatic pancreatic cancer that has worsened after two standard chemotherapy regimens. The phase III trial plans to enroll 226 adults and randomly assigns them in a 2:1 ratio to receive eithe…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This trial tests whether a virtual hub offering personalized exercise, nutrition, psychology, and peer support before and after colorectal cancer surgery can reduce complications within 30 days. About 564 adults in Australia having curative surgery will be randomly assigned to us…

This study tests whether adding the experimental drug INCA33890 to standard chemotherapy and bevacizumab helps people with metastatic colorectal cancer that is microsatellite stable (a type that doesn't respond well to immunotherapy). About 700 adults who have not had prior treat…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This clinical trial is testing a new biological therapy called GAIA-102, alone or combined with the immunotherapy pembrolizumab, for people with advanced stomach or pancreatic cancer that has spread and caused fluid buildup in the abdomen (malignant ascites). The study has two pa…

This study tests whether a probiotic called EXE-346 can help treat anal high-grade squamous intraepithelial lesions (HSIL) and reduce persistent high-risk HPV infection in people living with HIV. The trial will enroll 90 participants who will take the probiotic or a placebo daily…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

Researchers are comparing a new combination of disitamab vedotin, sintilimab, and S-1 against the standard regimen of trastuzumab plus chemotherapy, with or without sintilimab, for people with advanced HER2-positive gastric or gastroesophageal junction cancer. The trial enrolls a…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This study tests a new drug called TQB6411 in people with advanced esophageal cancer that has worsened after standard treatments. The drug is designed to target and attack cancer cells. The trial has two parts: first to find a safe dose, then to see if it shrinks tumors. About 10…

This early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…

This phase 2 trial is testing whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with lenvatinib, radiotherapy, and chemotherapy delivered directly to the liver can help people with hepatocellular carcinoma that has spread into the portal vein. The study aim…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a combination of two immunotherapy drugs (iparomlimab and toripalimab) plus bevacizumab and chemotherapy as a first treatment for advanced biliary tract cancer. It involves 32 adults aged 18-75 who have not had prior treatment for their advanced cancer. The goal …

This study is testing whether the immunotherapy drug dostarlimab (TSR-042), followed by standard chemoradiation and surgery, can effectively treat advanced mismatch repair deficient (dMMR) solid tumors. About 212 adults with locally advanced dMMR cancers will receive the drug int…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This study tests a new drug called daraxonrasib in people with pancreatic cancer who have already had surgery and chemotherapy. The goal is to see if taking the drug can delay or prevent the cancer from returning compared to just watching and waiting. About 500 adults will be ran…

This trial is investigating whether it is safe to skip the removal of a specific group of lymph nodes (the No.253 lymph nodes) during surgery for mid and low rectal cancer. The standard surgery removes these nodes, but this study compares the long-term survival of patients who ha…

This Phase 3 trial is testing whether adding a new targeted pill (INCB161734) to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 588 participants who have not had prior treatment for metastatic disease …

This study is testing whether a combination of three drugs—liposomal irinotecan, TAS102, and bevacizumab—can help people with metastatic colorectal cancer that has not responded to prior treatments. About 50 adults with mismatch repair proficient tumors will receive the drugs in …

This study is testing whether memantine, a drug currently used for Alzheimer's disease, can help slow the growth of liver cancer in people with advanced cirrhosis. The trial will enroll 12 adults with liver cancer that cannot be removed by surgery and who are not candidates for s…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This phase 3 trial tests whether adding the targeted drug zolbetuximab to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced stomach or gastroesophageal junction (GEJ) cancer live longer. The study enrolls 500 adults whose tumors have specific m…

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This study tests whether adding a non-invasive sound wave treatment (histotripsy) to standard chemotherapy can help people with advanced colorectal cancer that has spread to the liver. About 100 adults whose cancer cannot be removed by surgery will receive both treatments. The go…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This study is for people with HPV-related throat cancer who have surgery to remove the tumor. Normally, some patients also get radiation afterward to lower the risk of cancer coming back. This trial tests whether it's safe to skip that radiation if a blood test two weeks after su…

This phase 2 trial tests whether the drug TPST-1495 can reduce the number and size of polyps in the small bowel and colon of people with familial adenomatous polyposis (FAP), an inherited condition that greatly raises colon cancer risk. About 38 participants will take the drug by…

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…

This study tests an experimental drug called HRX215 in people who had part of their liver removed because colon cancer spread there. The drug is meant to help the liver grow back and work better after surgery. About 80 adults will take either HRX215 or a placebo for 28 days, and …

This early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

Researchers are testing whether adding an experimental drug called 2141-V11 to standard immunotherapy is safe for people with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma. Participants receive injections of 2141-V11 directly into their tumors along wi…

This early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …

This early-phase trial is testing whether combining an immunotherapy drug (nivolumab) with chemotherapy (fluorouracil) and an immune stimulant (interferon alpha 2b) can safely shrink or control fibrolamellar liver cancer that cannot be removed by surgery. The study will enroll 15…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This phase II trial tests a treatment called HIPEC, where heated chemotherapy drugs are placed directly into the abdomen during surgery. It is for people with pancreatic cancer that has spread to the lining of the abdomen. The study will enroll 40 participants to see if this appr…

Researchers are testing whether a combination of two drugs, atezolizumab and bevacizumab, can clear tiny amounts of cancer DNA from the blood of people whose gastrointestinal cancer was treated with curative intent. The trial enrolls 20 adults with colon, rectal, gastric, pancrea…

Researchers are testing a new device that uses endoscopic ultrasound to guide microwave energy directly into pancreatic and liver tumors that cannot be removed by surgery. The study enrolls 75 adults with locally advanced or metastatic cancer. The main goal is to see whether the …

This phase 3 trial is testing whether adding the targeted drugs calderasib and cetuximab to standard chemotherapy can help people with a specific gene mutation (KRAS G12C) in advanced colorectal cancer live longer without their cancer growing. About 477 participants will receive …

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This study tests an experimental drug called telisotuzumab adizutecan combined with standard chemotherapy in people whose colorectal cancer has spread. The goal is to see if the combination shrinks tumors and is safe. About 390 adults will take part at hospitals worldwide.

This study compares two treatments after surgery for stage III-IVA head and neck cancer: radiation alone versus radiation plus the chemotherapy drug cisplatin. The goal is to see which approach better prevents the cancer from returning, especially in patients with certain TP53 ge…

This phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assign…

This pilot study looks at whether closely monitoring and managing blood sugar levels can help people with pancreatic cancer. About 50 participants will wear a continuous glucose monitor during chemotherapy. Half will get intensive glucose management from an endocrinologist, while…

This study tests whether adding the drug zanidatamab to standard chemotherapy (with or without an immunotherapy) can help people with advanced HER2-positive bile duct cancer live longer without their cancer growing. About 286 adults with inoperable or metastatic bile duct cancer …

This study tests whether a new drug called pumitamig, combined with chemotherapy, works better than the current standard treatment (bevacizumab plus chemo) for people with advanced colorectal cancer that cannot be removed by surgery. About 990 adults who have not yet been treated…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This study tests a new surgery for early gastric cancer that uses two scopes (a laparoscope and an endoscope) to guide the removal of sentinel lymph nodes. The goal is to see if this approach is safe and effective. The study involves 36 people with early-stage stomach cancer.

This phase 3 trial compares a subcutaneous (under-the-skin) injection of tislelizumab to the standard intravenous (IV) infusion, both given with chemotherapy, as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has sp…

This study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in people with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the combination can shrink tumors and improve …

This phase 2 trial compares a rechallenge treatment (irinotecan plus cetuximab) against the current standard (trifluridine/tipiracil plus bevacizumab) for people with metastatic colorectal cancer whose disease has worsened after earlier therapies. Only patients with specific gene…

This Phase 3 trial is testing whether a new drug called rilvegostomig, combined with trastuzumab deruxtecan and chemotherapy, works better than the current standard treatment for HER2-positive stomach cancer that has spread. About 840 people whose tumors have a specific protein (…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This study is collecting information on how well the HistoSonics Edison System, which uses sound waves (histotripsy) to destroy liver tumors, works in everyday medical practice. Up to 5,000 adults with liver tumors will be followed for up to 5 years after treatment. The main goal…

This study tests a procedure called transarterial infusion chemotherapy (TAIC) for people with colorectal cancer that cannot be removed by surgery. Instead of giving chemo through a vein, TAIC delivers it directly to the tumor's blood supply, which may boost effectiveness and red…

This study tests whether adding a radioactive drug (177Lu-DOTA-TATE) to standard therapy (octreotide) helps control advanced neuroendocrine tumors of the gut or pancreas better than standard therapy alone. About 240 newly diagnosed patients with slow-growing but high-burden tumor…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

This early-phase trial tests a new drug called ASP2138, which helps the immune system attack cancer cells that have a specific marker (CLDN18.2). It is for people with advanced stomach, gastroesophageal junction (GEJ), or pancreatic cancer that cannot be removed by surgery or has…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This study tests the safety and effectiveness of targeted therapies or immunotherapies in people with metastatic colorectal cancer (cancer that has spread). Participants are assigned to a treatment based on specific biomarkers found in their tumor. The goal is to see if these per…

Researchers are testing whether combining abiraterone and dalpiciclib can shrink recurrent or metastatic salivary gland cancer that is AR-positive and HER-2-negative. The trial enrolls up to 36 adults who have no curative surgery or radiation options. Participants take both drugs…

This early-phase trial tests whether injecting a medical glue (Histoacryl®) into the pancreas during Whipple surgery can strengthen the connection between the pancreas and intestine and prevent dangerous leaks. The study involves 30 patients with soft pancreases and narrow ducts,…

This phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …

This study tests whether giving a short course of targeted drugs before surgery can improve outcomes for people with colorectal cancer that can be removed. About 197 participants will receive a treatment matched to their tumor's genetic makeup, followed by standard surgery. The g…

This study tests a new drug, WGI-0301, combined with sorafenib in 60 adults with advanced liver cancer that cannot be removed by surgery and has not responded to prior immunotherapy. The goal is to find the best dose and see if the combination can shrink tumors. Participants must…

This phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…

This study compares two standard approaches for Barrett's esophagus with low-grade dysplasia: regular monitoring with biopsies (surveillance) versus a procedure to remove or burn away precancerous cells (endoscopic eradication therapy). Researchers want to find out which method i…

Researchers are testing whether giving chemotherapy before surgery helps people with clearly resectable pancreatic head cancer or periampullary cancer live longer than going straight to surgery. The trial enrolls 262 participants and randomly assigns them to either mFOLFIRINOX ch…

This early-stage study tests a two-part system to find and treat metastatic cancer. First, a radioactive tracer is used to spot tumors on a PET scan. Then, a similar radioactive drug is given to deliver radiation directly to the cancer cells. The goal is to see if this approach i…

This trial tests whether a 12-week home-based exercise program can alter the gut microbiome in young adults (ages 18-50) with colorectal cancer who are undergoing chemotherapy. Participants are randomly assigned to either the exercise group or a waitlist control group. Researcher…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This phase 3 trial tests whether adding the experimental drug ASP2138 to standard chemotherapy and immunotherapy (pembrolizumab) helps people with a specific type of advanced stomach or gastroesophageal junction cancer live longer without their disease worsening. The study enroll…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This early-phase trial tests a drug called TTI-101 combined with a precise type of radiation (SBRT) in 18 people with pancreatic cancer that is borderline resectable or locally advanced. The goal is to see if the combination is safe and can improve how long patients live without …

This trial tests two chemotherapy strategies for people who have had surgery for malignant biliary tract tumors. One group receives hepatic arterial infusion chemotherapy, where drugs are delivered directly to the liver through a catheter. The other group takes capecitabine pills…

Pancreatic ductal adenocarcinoma often returns near where it started, even after surgery. This study tests whether a more thorough operation, called total mesopancreatic excision, can improve local disease control and survival. During pancreaticoduodenectomy, surgeons remove the …

This phase 2 trial tests whether pravastatin (a cholesterol drug) or a combination of pentoxifylline and vitamin E can prevent lymphedema and fibrosis (swelling and scarring) caused by radiation therapy in head and neck cancer patients. About 295 adults with oropharyngeal cancer …

This early-phase trial tests the safety and best dose of a drug called ulixertinib when given with cetuximab and/or encorafenib. It is for people with advanced colorectal cancer that has spread and who have already tried treatments targeting EGFR or BRAF. The goal is to find a do…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This phase II trial is testing whether alternating standard chemotherapy and immunotherapy with a targeted drug called pemigatinib can help people with advanced biliary tract cancers that have FGFR2 alterations. The study includes adults with cancer that cannot be removed by surg…

This clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…

This trial is testing a new type of radiation therapy that adapts daily to the exact shape and position of a pancreatic tumor. The goal is to deliver a high, tumor-killing dose while minimizing damage to nearby stomach and intestines. About 134 people with borderline resectable o…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

Researchers are testing a combination treatment for intrahepatic cholangiocarcinoma, a type of liver cancer that cannot be removed by surgery. The study gives participants Y-90 radioembolization, which delivers radiation directly to liver tumors, followed by six cycles of the che…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This clinical trial is looking at the best timing for local treatments like surgery or radiation in people with esophageal or stomach cancer that has spread to only a few spots. All participants first get 4 months of standard drug therapy. Then, depending on their response, they …

This study tests whether adding the immunotherapy drug atezolizumab to the standard drug imatinib can help control advanced gastrointestinal stromal tumors (GIST) that have stopped responding to other treatments. About 110 adults with inoperable or metastatic GIST will be randoml…

Researchers are testing whether adding oral fecal microbiota transplantation capsules can help control advanced hepatocellular carcinoma that has worsened during treatment with immune checkpoint inhibitors and tyrosine kinase inhibitors. The trial enrolls 30 adults with liver can…

Researchers test whether combining sacituzumab tirumotecan and tislelizumab can shrink advanced esophageal squamous cell carcinoma that has worsened after prior immunotherapy. The trial enrolls 28 adults whose cancer is not suitable for surgery or definitive chemoradiation. Parti…

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This trial is testing whether adding an experimental antibody called petosemtamab to standard chemotherapy can help people with a certain type of advanced colorectal cancer that has returned or spread. Participants will receive either petosemtamab plus chemotherapy or a standard …

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

Researchers are testing two investigational radiopharmaceuticals in adults with advanced solid tumors, including colorectal, pancreatic, biliary tract, gastric, esophageal, and head and neck cancers. First, participants receive SKL35502, an imaging agent that highlights tumors ca…

This study is testing whether giving radiation therapy along with immunotherapy before surgery can improve outcomes for people with sinonasal or anorectal mucosal melanoma, two rare and aggressive cancers. About 40 participants will receive combination immunotherapy (such as ipil…

Neuroendocrine tumors often keep growing despite treatment with somatostatin analogues, drugs that slow tumor growth and reduce hormone production. When that happens, doctors add peptide receptor radionuclide therapy (PRRT), a targeted radiotherapy, but they do not know whether c…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…

This phase 3 trial tests whether adding the experimental drug SHR-A1811 to standard chemotherapy and bevacizumab works better than standard therapy alone for people with advanced colorectal cancer who have not had prior treatment. About 300 participants will receive either the ne…

This study compares a new drug, zanzalintinib, to the current standard drug everolimus in people with advanced neuroendocrine tumors that have already been treated. The goal is to see which drug better slows tumor growth. About 440 participants will be randomly assigned to one of…

This phase 2 trial tests whether transplanting healthy gut bacteria (fecal microbiota transplant) can boost the effects of immunotherapy and chemotherapy in 30 people with advanced colon cancer that has spread to the liver. Participants receive the combination for six cycles, the…

This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 60 pe…

This study tests a wearable patch called MultiSense that tracks heart rate and other vital signs for five days after a patient leaves the hospital following major digestive surgery. The goal is to see if the patch allows high-risk patients to be discharged earlier while still cat…

Researchers are comparing two chemotherapy approaches for people with advanced pancreatic cancer that has not worsened after three months of initial treatment with mFOLFIRINOX. One group continues mFOLFIRINOX, while the other switches to gemcitabine plus nab-paclitaxel. The trial…

This phase 2 trial tests the drug velzatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to or cannot tolerate several standard treatments. The study aims to see if velzatinib can shrink or control the tumors and how safe it is. Par…

This Phase 3 trial tests a new drug called precemtabart tocentecan, alone or with bevacizumab, against a standard treatment for metastatic colorectal cancer that has progressed after prior therapies. About 1,020 participants will be randomly assigned to one of three treatment gro…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This Phase 2 trial is testing a new drug called Rina-S (rinatabart sesutecan) in about 160 people with advanced gastrointestinal cancers that have spread or cannot be removed. The drug is given alone through an IV, and everyone receives it—no placebo. The study will check if the …

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This trial tests whether adding radiofrequency ablation to standard chemotherapy and bile duct stenting helps patients with inoperable bile duct cancer. Radiofrequency ablation uses a catheter to deliver heat that destroys tumor tissue blocking the bile duct. Researchers compare …

This study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This early-phase trial tests whether adding an experimental drug called CTX-009 to standard chemotherapy (gemcitabine and cisplatin) plus immunotherapy (durvalumab) can safely treat advanced biliary tract cancer that cannot be removed by surgery. About 50 adults will receive the …

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This Phase 3 trial is testing whether a new targeted drug called sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly an immunotherapy (rilvegostomig), can help people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specifi…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This study looks at people with colorectal cancer that spread to the liver, who had good results from chemotherapy before surgery. After removing the liver tumors, half will restart the same chemo (FOLFIRI) and half will get no further treatment. The goal is to see if the extra c…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…

This phase 3 trial tests whether a new drug called petosemtamab, combined with chemotherapy, works better than the current standard treatment (cetuximab plus chemotherapy) for people with left-sided colorectal cancer that cannot be surgically removed or has spread. The study incl…

This early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This early-phase trial is testing whether adding an experimental drug called CA-4948 to standard chemotherapy (FOLFOX) and a targeted therapy (bevacizumab) is safe for people with metastatic colorectal cancer. About 24 adults whose cancer has spread and cannot be surgically remov…

Researchers are testing whether a short, focused course of radiotherapy combined with immunotherapy and chemotherapy can shrink locally advanced esophageal squamous cell carcinoma before surgery. Participants receive three cycles of camrelizumab plus nab-paclitaxel and carboplati…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…

Researchers are testing a three-part treatment for advanced colorectal cancer with a BRAF V600E mutation that has stopped responding to standard BRAF-targeted therapy. The trial combines ivonescimab, a drug that blocks two proteins involved in tumor growth and immune evasion, wit…

This Phase 3 trial is testing whether a combination of two targeted drugs, tunlametinib and vemurafenib, can help people with a specific genetic mutation (BRAF V600E) in metastatic colorectal cancer. About 165 participants will be randomly assigned to receive either the drug comb…

This trial is testing whether combining pidnarulex (a drug that blocks cancer cell growth) with cemiplimab (an immunotherapy that helps the immune system attack cancer) is safe and effective for people with advanced colorectal cancer that no longer responds to standard treatments…

This study compares two methods for finding precancerous colon polyps during colonoscopy. Both methods use water instead of air to inflate the colon and an AI system to spot polyps. One group also uses a special light filter called linked-color imaging. The goal is to see if the …

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This phase 3 trial compares a combination of two experimental oral drugs, zoldonrasib and daraxonrasib, against standard chemotherapy (gemcitabine plus nab-paclitaxel) as the first treatment for people with metastatic pancreatic cancer that has a specific KRAS G12D mutation. The …

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This trial tests whether the type of anesthesia given during esophageal cancer surgery affects how long patients stay free of cancer recurrence. Researchers will randomly assign about 1,600 adults with stage 1 to 3 esophageal cancer to receive either propofol-based total intraven…

This trial tests whether completely closing the wound left after removing large flat colon polyps (at least 20 mm) reduces complications like delayed bleeding or perforation. About 686 adults scheduled for polyp removal will be randomly assigned to either have the wound closed wi…

This early-stage trial tests a new cell-based gene therapy called RR001 given after chemotherapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study aims to check safety and find the best dose in a small group of 9 participants. It is n…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…

This phase 3 study tests whether a new drug called ivonescimab, combined with standard chemotherapy (FOLFOX), works better than the current standard treatment (bevacizumab plus FOLFOX) for people with metastatic colorectal cancer that has spread. About 600 adults who have not had…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This study tests a new drug, IDRX-42, against the current standard drug sunitinib in adults with advanced gastrointestinal stromal tumors (GIST) that have spread or can't be removed by surgery and have already been treated with imatinib. About 450 participants will be randomly as…

This phase 2 trial tests whether apatinib, taken as a daily pill, can control advanced stomach or gastroesophageal junction cancer in people aged 65 and older who cannot or will not undergo chemotherapy. Participants receive apatinib until the disease worsens or side effects beco…

This study looks at the best way to treat people with p53-mutant oral dysplasia (abnormal cells in the mouth) and early-stage oral cancer. About 636 adults will be placed into three groups based on their diagnosis and receive either monitoring, surgery, or surgery plus neck disse…

This early-stage trial tests a new drug called ONC-783 in 20 people with advanced solid tumors, including colorectal, ovarian, pancreatic, or breast cancer. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal is to find a safe d…

This study tests whether combining Lutathera (a radioactive drug given by IV) with Olaparib (a pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several cycles. The goal is to fin…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…

This phase II trial tests whether combining anlotinib, benmelstobart, and hepatic arterial infusion chemotherapy (HAIC) can shrink tumors in people with unresectable hepatocellular carcinoma, the most common type of liver cancer. The study enrolls adults aged 18 to 75 with confir…

This study tests an experimental drug called TNG462 for people with advanced solid tumors that have a specific genetic deletion (MTAP). The drug is taken by mouth and aims to slow or stop tumor growth. The trial has two parts: first, finding the safest dose, and then testing that…

This early-stage trial tests a new drug called INBRX-109 in people with advanced solid tumors, including Ewing sarcoma and colorectal cancer. The drug is designed to attach to a protein on cancer cells and trigger their death. The main goals are to check safety and see if the dru…

This study compares two drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that hasn't been treated yet. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combo works b…

This study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …

This phase 2 trial tests whether a combination of three drugs—avutometinib, defactinib, and cetuximab—can help control advanced colorectal cancer that has stopped responding to standard anti-EGFR treatment. About 33 participants will receive the drugs orally and intravenously. Th…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This study is observing how well the drug fruquintinib works for people with metastatic colorectal cancer who have already tried standard treatments. About 150 participants in Germany will be treated as part of their normal care, and researchers will track tumor response, surviva…

This study tests a surgery called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with certain pancreatic tumors who are at high risk for a dangerous leak after standard surgery. The procedure removes the entire pancreas and transplants the insulin-making…

This trial tests whether adding an experimental drug called HDM2017 to standard chemotherapy and bevacizumab can safely shrink tumors in people with advanced colorectal cancer. The study includes adults aged 18 to 75 whose cancer has spread or cannot be removed by surgery. Resear…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This study tests a new treatment plan for people with advanced liver cancer that has spread to blood vessels or a few other spots. The plan combines chemotherapy directly into the liver, two immunotherapy drugs, a targeted therapy, and precise radiation. The goal is to see if thi…

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This early-phase study tests a new treatment for people with advanced pancreatic cancer that has spread and has a specific mutation called KRAS G12D. The treatment uses tiny particles called exosomes to deliver a molecule that blocks the mutated gene. The goal is to find the best…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …

This phase 2 trial tests whether a single injection of IP-001, given right after standard liver cancer ablation or surgery plus ablation, can help keep the cancer from coming back. About 126 adults with intermediate to high risk of recurrence will be followed for at least two yea…

This early-stage study tests a combination of two drugs—trastuzumab deruxtecan and azenosertib—in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and check for…

This study compares a new technique called total underwater colonoscopy (using water instead of gas) to the standard method in over 1,000 people undergoing screening after a positive stool test. The goal is to see if water helps doctors find more flat, hard-to-spot polyps that ca…

This early-stage study is testing a new treatment for people with metastatic colorectal cancer that has stopped responding to standard therapies. The treatment uses a two-step process to deliver a radioactive particle directly to cancer cells, aiming to control the disease. About…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …

This Phase 3 study tests whether adding the targeted drug sotorasib and another drug called panitumumab to standard chemotherapy (FOLFIRI) works better than standard chemo alone (with or without bevacizumab) for people with metastatic colorectal cancer that has a specific KRAS G1…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This trial tests whether giving magnesium sulfate through an IV during colorectal cancer surgery can dampen the body's inflammatory response afterward. Researchers will measure blood markers like white blood cells, C-reactive protein, and neutrophils in 52 patients, and also trac…

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus chemotherapy, or a stand…

Researchers are testing whether advanced ultrasound techniques combined with machine learning can improve the detection and characterization of liver cancer compared to standard ultrasound. The study enrolls 200 adults who have a focal liver lesion visible on ultrasound or are in…

Researchers at Ruijin Hospital are testing two PET imaging tracers, FAPI and Grazytracer, to see if they can predict how well advanced gastric cancer responds to preoperative immunotherapy. The study enrolls 120 adults with resectable or advanced gastric cancer. Participants rece…

This study is testing a new type of PET/CT scan called [¹⁸F]FAPI-74 to see if it can better detect when stomach or esophageal cancer has spread to other parts of the body. About 200 adults with these cancers will receive one dose of the scan tracer and be followed for up to 3 mon…

This phase 3 trial is testing a new type of PET scan that uses a radioactive tracer called [18F]FAPI-74 to detect whether pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the tracer and then be scanned. The …

This study is testing new, easy-to-use screening tools for colorectal cancer (CRC) in over 4,000 adults across Europe. Participants provide blood, breath, stool, and cheek swab samples, which are analyzed for biomarkers, genetic risks, and chemical patterns. The goal is to develo…

Researchers test whether giving people education materials and free access to screening helps them get checked for colorectal cancer and hepatitis C. The trial enrolls adults ages 45 to 75 who receive care at community health centers and are not up to date on these screenings. Pa…

This study aims to see if a new office-based test (EsoCheck balloon and EsoGuard lab test) can accurately detect Barrett's esophagus in people who do not have chronic heartburn. Barrett's esophagus is a condition that can lead to esophageal cancer, but it is often missed in peopl…

Researchers are evaluating a dynamic risk prediction model for severe myelosuppression in adults with nasopharyngeal carcinoma who receive systemic anticancer treatment. The model estimates the risk of grade 3 or higher anemia, low platelets, or low white blood cells during thera…

Researchers are studying whether a digital management platform can help diagnose liver cancer at an earlier stage in people with chronic liver disease. The study enrolls adults aged 18 to 75 with conditions such as chronic hepatitis B. The platform tracks patients and guides stan…

This phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …

Researchers are testing whether a fluorescent dye called cRGD-ZW800-1 can help surgeons see laryngeal and hypopharyngeal tumors more clearly during total laryngectomy. The trial has two parts: first, to find the best dose of the dye by measuring how brightly it lights up tumor ti…

Researchers are testing whether measuring aneuploidy (abnormal chromosome numbers) in cell-free DNA from peritoneal lavage fluid can improve the detection of gastric cancer that has spread to the abdominal lining. The study enrolls adults with gastric cancer and non-cancer contro…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

Researchers are studying whether a blood test called Guardant360 can measure how well cancer treatment is working in people with advanced lung, colorectal, or breast cancer. The test looks for tumor DNA that cancer cells release into the bloodstream. Participants give blood sampl…

Researchers are testing whether a 3D imaging model called 3D-PANC MSP is better than standard CT scans at showing how pancreatic tumors respond to chemotherapy before surgery. The study includes 70 patients with borderline or locally advanced pancreatic adenocarcinoma who have re…

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This study tests a new radioactive tracer called 68Ga-GPC3 that targets a protein found on liver cancer cells. About 40 adults with suspected or confirmed hepatocellular carcinoma will receive both this new tracer and a standard tracer (18F-FDG) for PET/CT scans. Researchers will…

Researchers are testing a new PET/CT imaging tracer designed to spot insulinomas, rare pancreatic tumors that cause dangerously low blood sugar. These tumors are often tiny and easy to miss on standard CT, ultrasound, or PET scans. The tracer targets a protein called GLP-1R that …

This study tests a new way to use contrast-enhanced ultrasound (CEUS) to see if liver cancer treatment (ablation) worked. Researchers will compare the new CEUS criteria with standard CT or MRI scans in 200 adults. If accurate, this could make follow-up safer and easier by avoidin…

This trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…

This trial tests whether a single injection of a radioactive tracer called 68Ga/18F-Exendin 4 can improve PET/CT scans for finding tumors that carry GLP-1 receptors. Researchers will enroll 500 adults with suspected or known tumors, including insulinomas, and measure how brightly…

This study is testing whether a blood test can accurately identify colorectal cancer or polyps in adults referred for suspected lower GI cancer. Participants provide a blood sample during their routine diagnostic visit, and their results are compared to their final diagnosis. The…

Researchers are testing whether a radioactive tracer called 68Ga/18F-PSMA/PSFA can improve PET/CT scans for finding tumors in people with PSMA-related cancers, including prostate and liver cancer. The study will enroll 500 adults with suspected, newly diagnosed, or previously tre…

This study is testing a new, single-use scope called the Dragonfly™ Digital Pancreaticobiliary System. It is designed to help doctors see inside the bile and pancreatic ducts during an endoscopy. The study will enroll up to 75 adults with bile duct stones or narrowings (stricture…

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …

Researchers are testing whether a combination immunotherapy called iparomlimab and tuvonralimab can prevent liver cancer from returning after surgery in patients whose tumors are at high risk of coming back. Participants receive one dose of the immunotherapy before surgery to rem…

Large colorectal polyps can turn into cancer, so doctors remove them during a colonoscopy. Even after removal, polyps often grow back. This trial compares two methods for sealing the area where the polyp was removed: one uses a water jet to lift tissue and then burns it with argo…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This study tests whether adding the antifungal drug itraconazole to standard ablation therapy can prevent esophageal cancer in people with high-risk Barrett's esophagus. About 64 participants will receive either itraconazole or a placebo alongside their usual endoscopic ablation.…

This early-phase study tests the safety of a drug called ONC201 (dordaviprone) in 36 adults at high risk for colorectal cancer due to familial adenomatous polyposis (FAP) or a history of many polyps. The drug aims to kill precancerous cells without harming normal ones. Researcher…

This early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe an…

This study looks at whether adding pelvic floor physical therapy before standard radiation treatment can help reduce pain and sexual problems in women with cervical, vaginal, vulvar, uterine, or anal cancer. About 20 participants will receive education on using a vaginal dilator …

This trial compares a new surgery called partial stomach-partitioning gastrojejunostomy (SPGJ) to the standard surgery for relieving stomach blockage in advanced gastric cancer. The goal is to see which surgery better helps patients eat normally, with fewer complications like del…

This study tests an 8-week program of nutrition advice, exercise, and psychological support for people with pancreatic or esophageal cancer before they have surgery. The goal is to see if patients can complete the program and if it helps them prepare for surgery. Only 9 patients …

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This Phase 3 trial tests whether the experimental drug paltusotine can reduce flushing and diarrhea in adults with carcinoid syndrome caused by neuroendocrine tumors. About 141 participants will receive either paltusotine or a placebo daily for 12 weeks. The study measures how mu…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether a remote exercise and nutrition program is practical and acceptable for people with pancreatic cancer who are waiting for surgery. Participants will use a Fitbit, get nutrition advice, and do resistance training at home. The goal is to see if this 'prehab…

This study compares two ways to manage pain after minimally invasive surgery for esophageal cancer: a paravertebral catheter versus the standard epidural. The goal is to see if the paravertebral approach provides similar or better recovery quality by day three. About 506 adults h…

This study tests a flexible palliative care program for people with advanced heart failure or certain cancers. The program adds more team members—like a social worker or nurse—as symptoms get worse. The goal is to improve quality of life and match care to each person's changing n…

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

Researchers are testing whether giving nimodipine through an IV before, during, and after open colectomy can reduce the amount of anesthetic and opioid painkillers patients need. The trial enrolls 40 adults with bowel cancer scheduled for open surgery. Participants receive either…

Cancer treatment often leaves patients with a deep, lasting tiredness that few treatments can fix. Researchers are testing whether guarana, a caffeine-rich Amazonian plant, can reduce that fatigue and improve daily life. The study gives 60 people with breast, lung, colorectal, ce…

This phase II trial tests whether a standardized acupuncture protocol can reduce peripheral neuropathy, a common and often lasting side effect of oxaliplatin chemotherapy. Participants are adults with gastrointestinal solid tumors who stopped oxaliplatin-based treatment and still…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This study tests whether telehealth self-management coaching sessions can improve quality of life for people with metastatic pancreatic cancer and their family caregivers. Participants will attend virtual coaching sessions focused on managing physical symptoms, emotional well-bei…

After surgery to remove a benign parotid tumor, some people develop salivary fistulas or sialoceles, which are collections of saliva that can leak or cause swelling. This pilot study tests whether injecting a long-acting local anesthetic called bupivacaine, combined with a steroi…

This study tests whether a prehabilitation (prehab) exercise program can reduce memory loss, forgetfulness, and brain fog caused by chemotherapy in older adults with colorectal cancer. Researchers will enroll 86 physically inactive people aged 60-85 who are about to start chemoth…

This phase 3 trial tests whether a lozenge called BupiZenge, which contains the long-acting painkiller bupivacaine, can relieve mouth pain from radiation therapy better than the standard lidocaine rinse. About 150 adults with head and neck cancer will be randomly assigned to one …

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This study tests whether personalized self-management training helps people with gastrointestinal cancer adopt healthier habits like better diet and more exercise. 120 participants will be randomly assigned to either personalized or standard training for 6 weeks. The goal is to s…

This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…

This pilot study tests whether a community health worker (promotora) can help Latinx patients recently diagnosed with colorectal cancer. Sixty participants will either get a navigator for up to 6 months or just a list of social services. The goal is to see if this support improve…

This study compares two types of nerve blocks—coeliac plexus block and splanchnic nerve block—to see which one reduces pain better in adults with upper abdominal cancer. Forty-four participants will receive one of the procedures and be monitored for pain, opioid use, and quality …

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

Researchers are studying whether a next-generation radiation delivery system can run a complete treatment workflow while patients hold their breath. The trial enrolls about 20 adults with tumors in the chest or upper abdomen who are already scheduled for stereotactic body radiati…

This study is for people with pancreatic cysts or other pancreas issues. Researchers will collect blood, tissue, and scan data from over 1,100 participants to create a large database. The goal is to develop noninvasive tools that predict which cysts may become cancerous, helping …

This trial tests whether an AI tool can help surgeons better predict risks for patients undergoing colorectal cancer surgery. About 1,200 patients across Denmark will be randomly assigned to have their risk assessed by a surgeon using standard methods or with AI assistance. The g…

Researchers are exploring whether an experimental compound called BPR001-615 can reduce the growth of colorectal cancer cells taken directly from patients during surgery. The study also measures levels of a protein called BiP in blood and tumor tissue to see whether it could serv…

This study looks at families where multiple members have had small bowel carcinoid tumors, a rare and slow-growing cancer. Researchers want to learn how the disease develops, improve early detection, and find the genes that may cause it. Participants, including those with and wit…

This study is developing and testing a mobile app designed to help Black people with pancreatic cancer learn about and discuss clinical trials with their doctors. The goal is to increase their participation in these trials, which is currently much lower than for White patients. R…

This study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…

This study looks at whether a simple blood test can help doctors decide if rectal cancer patients can avoid surgery and keep their rectum. Researchers will measure tiny bits of tumor DNA in the blood (ctDNA) before, during, and after standard treatment. The goal is to see if chan…

This study tests whether a video and personal guidance can help Black, Latinx, and older adults with cancer get genetic testing. Genetic testing is often needed to join precision cancer trials. The goal is to make trial enrollment more equitable. About 210 people with gastrointes…

This study looks at whether genetic information from tumors can help doctors choose better treatments for pancreatic cancer. About 200 adults with early or locally advanced pancreatic cancer will receive standard chemotherapy and provide blood, tissue, and fluid samples for genet…

This study aims to better understand why some people experience dangerously low blood sugar (hypoglycemia), especially after fasting. Researchers will admit 1,500 adults to the NIH Clinical Center for controlled fasting and a series of blood tests to measure insulin and other fac…

This study aims to see if a custom-made tumor culture system can predict how oral cavity cancer responds to the immunotherapy drug pembrolizumab before surgery. Twenty participants will provide a biopsy, receive pembrolizumab as standard care, and then have their tumor analyzed. …

This study enrolls people with endocrine tumors (such as thyroid, parathyroid, adrenal, or pancreatic tumors) who are scheduled for surgery or biopsy. Researchers collect samples of the tumor, nearby healthy tissue, blood, and urine to analyze genetic and molecular changes. The g…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study is testing a new approach to personalize cancer treatment for people with colorectal or pancreatic cancer. Researchers will take a small sample of a patient's tumor, grow it in the lab, and test different drugs on it to see which one works best. The goal is to see if t…

This study will test if measuring hand grip strength during clinic visits is practical and useful for adults with pancreatic cancer. Fifty participants will squeeze a handheld device and fill out well-being questionnaires alongside their regular care. Researchers want to see if c…

This study tests a new imaging method called qDSA that measures blood flow in real time during liver embolization, a procedure that blocks blood supply to tumors. Up to 20 participants will have qDSA and ultrasound images taken before, during, and after the procedure. The goal is…

This study aims to learn more about oropharyngeal carcinoma, a type of throat cancer that can be linked to HPV. Researchers will collect blood samples from 1,000 patients before treatment and at six follow-up visits, and also gather tumor tissue when available. The goal is to bet…

This study tracks 125 cancer patients receiving standard chemotherapy and radiation to understand why they feel tired. Researchers will collect blood, stool, and survey data before, during, and after treatment. The goal is to find patterns that could help predict and manage fatig…

Researchers are studying whether frailty measured before surgery can predict how older adults recover after an operation for gastrointestinal cancer. The trial enrolls 100 people aged 60 and older who are scheduled for elective surgery. Before the operation, each participant rece…

This study tests whether sending text messages can encourage homeless adults aged 45-75 to complete colorectal cancer screening. About 588 participants from shelter clinics in New York City will be randomly assigned to receive SMS reminders or standard care. The goal is to see if…

This study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …

This study looks at whether it is safe to skip placing a drain in the belly after surgery to remove part of the pancreas. About 234 adults having this surgery will be randomly assigned to get a drain or not. The goal is to see if not using a drain leads to fewer serious problems …

Researchers are studying whether older adults with gastrointestinal cancer who have low muscle mass and strength before surgery recover worse afterward. The study enrolls about 100 people aged 60 and older who are scheduled for elective cancer surgery. Before their operation, par…

This study collects blood and tumor samples from people with gastrointestinal cancers, such as stomach, liver, or colon cancer. Researchers want to learn how the immune system responds to these cancers. Participants give samples over several visits but receive no treatment as par…

This study looks at whether preserving the left colic artery during colon or rectal cancer surgery helps keep the remaining colon well-supplied with blood. Surgeons will temporarily clamp the main artery and use a green dye to measure blood flow. The goal is to see if this techni…

This study looks at genetic changes in metastatic pancreatic cancer to see if they can help guide treatment choices. Researchers will take tumor biopsies and blood samples from 190 patients starting chemotherapy. The main goal is to see if genetic test results can be returned wit…

This study tests a small device called Seismofit that sticks to the chest and measures heart vibrations to estimate fitness in under three minutes. Researchers want to see if it can predict complications like pneumonia and hospital stay length in 164 oesophageal cancer patients u…

This study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…

This study gathers blood, saliva, urine, and stool from up to 1,600 children with recurrent or chronic pancreatitis. Researchers look for genetic markers that might increase the risk of pancreatic cancer later in life. No treatment is given—the goal is simply to learn more about …

This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to cancer treatment can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online …

Researchers at a single center are observing about 1,000 patients with hepatocellular carcinoma who receive systemic therapies. The study tracks overall survival, progression-free survival, and tumor response using standard imaging criteria. It also checks whether hepatitis C dru…

This study looks at whether a thorough health assessment before liver surgery can help older patients (70+) have fewer serious complications and recover better. Researchers will give 242 participants a special geriatric evaluation that checks frailty, memory, nutrition, and daily…

This study looks at people who have a gene variant (called a secondary finding) that was found during genetic testing for another reason. Researchers want to understand how these variants affect health, how people respond to the news, and whether they follow medical advice. Up to…

This study looks at whether an improved endoscopic ultrasound (EUS) can better find cancer in lymph nodes of people with bile duct cancer. About 250 patients with presumed resectable cancer will get the enhanced EUS before surgery. The goal is to see how many patients are spared …

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

This study looks at whether a new drug called UCB8600 can stop mast cells in the gut from overreacting, which may cause pain in people with irritable bowel syndrome (IBS). Researchers will take gut tissue from 60 people (some with IBS, some healthy) and treat it with UCB8600 in t…

Researchers are observing people with small liver cancer, cirrhosis, and an overactive spleen who undergo laparoscopic liver surgery combined with spleen removal. The study enrolls 30 adults with low platelet counts and follows them for two years after surgery. It tracks changes …

This study looks at how viruses change the environment around tumors in people with lymphoma, lung cancer, or anal cancer. Researchers will analyze blood and tumor samples from 254 patients to understand why some cancers resist treatment. The goal is to find new ways to make anti…

This study reviews the medical records of about 4000 people who had surgery for esophageal cancer. The goal is to see how the amount of cancer left at the edges of the removed tissue affects how long people live. No new treatments are given; the study only looks at past informati…

Researchers at Lille University are following 350 people, including cancer patients recently diagnosed with breast, gynecological, testicular or digestive cancer, their caregivers, and healthcare professionals. Over one year, participants answer questionnaires about post-traumati…

Researchers are studying whether stomach cancers that start near the esophagus differ from those in the rest of the stomach. They collect saliva, blood, stool, and tissue samples from 120 adults with stomach cancer and compare them with healthy controls. Using advanced molecular …

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…

This study will follow about 4,490 adults with liver or bile duct cancer who are receiving durvalumab-based treatment as part of their routine care. Researchers want to see how long patients live and how well the treatment works outside of clinical trials. The goal is to gather r…

Researchers at IRCCS San Raffaele are creating a registry of images and videos from endoscopic ultrasound procedures performed to investigate pancreatic diseases. The study will gather data from about 12,000 patients with conditions like pancreatitis, pancreatic cancer, and neuro…

This study tests whether giving heated chemotherapy directly into the abdomen (HIPEC) can increase a protein called PD-L1 on stomach cancer cells that have spread to the lining of the belly. Higher PD-L1 levels might make these cancers more responsive to immunotherapy drugs. The …

This study is gathering health information from 2,000 adults with primary sclerosing cholangitis (PSC) to build a real-world data comparator group. The goal is to help design and run future drug trials more efficiently by providing a control group from real patient experiences. P…

Researchers are creating a biobank of biological samples and clinical data from 2000 adults with various pancreatic conditions, including pancreatitis and pancreatic cancer. The goal is to investigate how genetic predisposition and environmental exposures interact to trigger thes…

This study compares two ways to rebuild the jaw after oral cancer surgery: standard free-hand surgery versus using 3D-printed guides made from virtual planning. About 420 adults needing jaw reconstruction will be randomly assigned to one method. The main goal is to see which appr…

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…

This study compares two ways of monitoring pancreatic cysts—more frequent versus less frequent scans—and looks for biomarkers in the blood that might help predict cancer risk. About 770 adults aged 50 to 75 with at least one cyst will take part. The goal is to find out which moni…

This early phase trial is testing several targeted drugs in people with pancreatic cancer to see how they affect tumor biology. Researchers will compare tumor samples taken before and after treatment to understand which drugs might work best. The goal is not to treat the cancer d…

This observational study follows 8,000 people with pancreatic cancer to map their real-world diagnostic and treatment journeys. Researchers will track overall survival and look for factors that influence treatment decisions and outcomes, including patient-reported experiences. Th…

This study will follow about 579 adults who need surgery to remove part or all of their pancreas but do not have diabetes before the operation. Researchers want to see how often new diabetes develops after surgery and whether the amount of pancreas removed changes that risk. The …

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…